Skip to search formSkip to main contentSkip to account menu

golvatinib

Known as: 1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-N'-(4-fluorophenyl)- 
An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

c-Met/VEGFR-2 Kinase Inhibitor E7050

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Design, synthesis and biological evaluation of 4-(pyridin-4-yloxy)benzamide derivatives bearing a 5-methylpyridazin-3(2H)-one fragment.
2020
2020
Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients
Backgrounds: The clinical features of autosomal dominant polycystic kidney disease (ADPKD) differ among patients even if they… 
2014
2014
Abstract 2980: Maximizing the efficacy of anti-angiogenesis cancer therapy: A multi-targeting strategy by tyrosine kinase inhibitors
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Although vascular endothelial growth factor (VEGF… 
2014
2014
Cancer Therapy : Clinical A Phase I , Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor , Golvatinib , in Patients with Advanced Solid Tumors
Purpose: Receptor tyrosine kinases c-Met and Ron transduce signals regulating cell migration and matrix invasion. This phase I… 
2014
2014
484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080)
2013
2013
Abstract 1619: Combination of VEGFR inhibitor lenvatinib (E7080) and Met/EphB4 inhibitor golvatinib (E7050) overcomes VEGFR inhibitor-resistant tumor vascular.
Vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for the treatment of several types of tumors, however… 
2012
2012
Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors.
Background: Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase and… 
2012
2012
Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally BID to patients with advanced solid tumors.
3079 Background: Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase… 
2012
2012
Reply to P. Blanchard et al
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)